NeuroMetrix, Inc. Announces Date for Second Quarter 2021 Financial Results Conference Call
NeuroMetrix, Inc. (Nasdaq: NURO) announced it will release its 2021 second quarter financial results on July 22, 2021, before market opening. A conference call will follow at 8:00 a.m. ET on the same day to discuss these results and related business developments. Investors can access the call by dialing 844-787-0799 in the U.S. or 661-378-9630 internationally, using confirmation code 4269315. Financial reports will be available on the company's website under 'Investor Relations'.
- None.
- None.
WOBURN, Mass., July 15, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2021 second quarter financial results before the opening of the market on July 22, 2021. The Company will host a conference call at 8:00 a.m., Eastern Time on July 22, 2021 to discuss its financial results as well as business developments affecting the Company.
The conference call may be accessed in the United States by dialing 844-787-0799 and using the confirmation code 4269315. Internationally, the conference call may be accessed by dialing 661-378-9630 and using the same confirmation code. The earnings press release and accompanying condensed financial statements will be accessible from the Company's website at www.NeuroMetrix.com under the "Investor Relations" tab.
A replay of the conference call will be available starting two hours after the call by dialing 855-859-2056, domestically and 404-537-3406, internationally. The confirmation code to access the replay is 4269315. The replay will be available for one week after the conference call.
About NeuroMetrix
NeuroMetrix is an innovation-driven company focused on the development and global commercialization of non-invasive medical devices for the diagnosis and treatment of pain and neurological disorders. The Company has three commercial products. DPNCheck® is a diagnostic device that provides rapid, point-of-care detection of peripheral neuropathies. ADVANCE® is a diagnostic device that provides automated, in-office nerve conduction studies for the evaluation of focal neuropathies. Quell® is a wearable neurostimulation device indicated for symptomatic relief of lower extremity chronic pain that is available over-the-counter. For more information, visit www.NeuroMetrix.com.
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
neurometrix.ir@neurometrix.com
Source: NeuroMetrix, Inc.
FAQ
When will NeuroMetrix release its Q2 2021 financial results?
What time is the NeuroMetrix conference call on July 22, 2021?
How can I access the NeuroMetrix conference call?
Where can I find the financial statements for NeuroMetrix?
